November 9, 2006 – Two biomedical companies, ActivBiotics and Thermage, lowered their prospective ranges prior to pricing tonight; 3M sold its drug business for $2.1 billion; MedImmune parted with its enriched immunoglobulin product for $120 million; Targacept reported positive data from a major depressive disorder drug; Enzon released pre-clinical data showing proof of principle for a cancer drug; Pozen submitted a full response to the Approvable letter it received for migraine treatment Trexima; Perrigo recalled 11 million bottles of acetaminophen caplets; MedImmune filed an IND for its cell-culture manufactured flu vaccine; Angiotech reported success for Vascular Wrap, a paclitaxel-eluting mesh; a cancer drug from ArQule was well-tolerated and showed signs of efficacy; and EntreMed reported positive preclinical data for a cancer drug candidate. The Centient Biotech 200™ fell 79 points to 3934, a 2% loss. More details...
